CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

PR79494

MELBOURNE, Australia, July 2, 2019 /PRNewswire=KYODO JBN/ --

-- Novel real world evidence for AFSTYLA(R) and IDELVION(R) to be highlighted

Global biotherapeutics leader CSL Behring (https://c212.net/c/link/?t=0&l=en&o=2514141-1&h=2330612868&u=http%3A%2F%2Fwww.cslbehring.com%2F&a=CSL+Behring )

announced today that the company will support the presentation of new data

from its recombinant coagulation factor programs at this year's International

Society on Thrombosis and Haemostasis (ISTH) (https://c212.net/c/link/?t=0&l=en&o=2514141-1&h=3624736756&u=https%3A%2F%2Fwww.isth2019.org%2F&a=International+Society+on+Thrombosis+and+Haemostasis )

Congress in Melbourne, Australia, 6-10, July, 2019. In addition to supporting

15 posters and one oral presentation, the company will also host two satellite

symposiums during the meeting.  The ISTH congress presents an opportunity for

leaders in hematology and thrombosis research to exchange new findings and

discuss advances in patient care.  

"Real world evidence can provide deep new insights that complement data

acquired in clinical trials and can unlock the promise of novel bleeding

disorder treatments", said Andrew Cuthbertson, Chief Scientific Officer and R&D

Director, CSL Limited. "These presentations demonstrate our commitment to

improving treatments and will provide valuable understanding to patients and

physicians when creating a care plan."

Seven poster presentations, an oral presentation and a satellite symposium will

add to the growing body of evidence demonstrating the safety and efficacy of

AFSTYLA(R) [Antihemophilic Factor (Recombinant), Single Chain]. AFSTYLA (also

known as rVIII-SingleChain), CSL Behring's recombinant factor VIII single-chain

therapy for haemophilia A, is approved in over 40 countries including

Australia, Japan, the European Union, United States, and Switzerland.

Five posters and a satellite symposium will highlight new IDELVION(R)

[Coagulation Factor IX (Recombinant), Albumin Fusion Protein] data. IDELVION

(also known as rIX-FP), CSL Behring's long-acting recombinant factor IX albumin

fusion protein for haemophilia B, is approved in over 40 countries including

Australia, Japan, the European Union, United States and Switzerland.

Real World Evidence Posters:

    - Real-world use of recombinant factor IX albumin fusion protein (rIX-FP)

      in patients with hemophilia B: A multinational prospective, non-

      interventional, post-marketing surveillance study (Johannes Oldenburg) -

      PB0281 [7 July, 18:30 - 19:30]

    - Comparison of FVIII prophylaxis treatment regimen and associated clinical

      outcomes between rVIII-SingleChain and other rFVIII products commonly

      used in German Hemophilia A patients (Songkai Yan)  - PB0282 [7 July,

      18:30 - 19:30]

    - Real-world utilization and bleed rates in patients with hemophilia B who

      switched to recombinant factor IX fusion protein (rIX-FP) in Italy,

      Belgium and the United (Patrick Sommerer) - PB0691 [8 July, 18:30 -

      19:30]

    - Real-World Consumption rVIII-SingleChain: US Population Experience

      (Michael Wang) - PB0699 [8 July, 18:30 - 19:30]

    - Prophylactic Factor VIII use and clinical outcomes in German Hemophilia A

      patients who switched to extended dosing intervals with long-acting rVIII-

      SingleChain (Songkai Yan) - PB0733 [8 July, 18:30 - 19:30]

    - Analysis of recombinant FVIII consumption and treatment outcomes and

      comparison with other FVIII products based on US Hemophilia A prophylaxis

      patient charts (Songkai Yan) - PB1456 [9 July, 18:30 - 19:30]

Research Posters:

    - Determining the Specificity of Commercially Available Thrombin Substrates

      (S. Praporski) - PB0111 [7 July, 18:30 - 19:30]

    - Mechanisms for the Clearance and Recycling of Recombinant VWF D'D3

      Albumin Fusion Protein (Kim Lieu)  PB0071 [7 July, 18:30 - 19:30]

    - Efficacy and safety of rIX-FP in surgery: an update from a phase 3b

      extension study (Claude Négrier) - PB0734 [8 July, 18:30 - 19:30]

    - Population Pharmacokinetics of rVIII-SingleChain in Obese Previously

      Treated Patients with Severe Hemophilia A in Study CSL627_1001 (William

      McKeand) - PB0709 [08.07.19, 18:30-19:30]

    - Higher trough levels, improved quality of life and reduced costs when

      switching to rIX-FP in a severe hemophilia B patient with considerable

      neurological disability (Rosario Maggiore) - PB0684 [8 July, 18:30 - 19:30]

    - Systematic review of efficacy and factor consumption of long-acting

      recombinant factor VIII products for prophylactic treatment of hemophilia

      A (Songkai Yan) - PB0730 [8 July, 18:30 - 19:30]

    - Treatment Success of rVIII-SingleChain in Obese Previously Treated

      Patients with Severe Hemophilia A in study CSL627_1001 (Johnny Mahlangu)

      - PB1455 [9 July, 18:30 - 19:30]

    - Long-term efficacy and safety of recombinant factor IX fusion protein

      (rIX-FP) in previously treated patients with hemophilia B: Results from a

      phase 3b extension study (Maria Elisa Mancuso) - PB1453 [9 July, 18:30 -

      19:30]

    - The Role of HLA-class-II (HLAcII) Molecules in Determining the

      Immunogenicity Potential of Therapeutic Factor VIII Proteins (tFVIIIs) in

      Hemophilia A (HA): The Gate Keeper Hypothesis (Vincent Diego) - PB1183 [9

      July, 18:30 - 19:30]

Oral Presentation:

    - Factor VIII (FVIII)-Haplotype Mismatch Increases Risk of Inhibitor

      Development in the Treatment of Hemophilia A (Tom Howard) - OC76.5 [10

      July, 11:15 - 11:30 Meeting Room 219/220]

Symposia:

    - Taking a Flexible Approach in Hemophilia B - Sunday, 7 July, 13:15-14:30

      Meeting Room 212/213

    - Improving Outcomes in Hemophilia A - Tuesday, 9 July, 13:15-14:30 Meeting Room 212/213

In addition, CSL Behring representatives will be available in the exhibition

hall (booth numbers 701 & 800) throughout the congress. The exhibit will

highlight CSL Behring's 30 years of experience and broad portfolio of treatment

options for patients living with inherited and acquired bleeding disorders.

About CSL Behring

CSL Behring (https://c212.net/c/link/?t=0&l=en&o=2514141-1&h=2330612868&u=http%3A%2F%2Fwww.cslbehring.com%2F&a=CSL+Behring )

is a global biotherapeutics leader driven by its promise to save lives.

Focused on serving patients' needs by using the latest technologies, we develop

and deliver innovative therapies that are used to treat coagulation disorders,

primary immune deficiencies, hereditary angioedema, inherited respiratory disease,

and neurological disorders. The company's products are also used in cardiac surgery,

organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL

Plasma. The parent company, CSL Limited (https://c212.net/c/link/?t=0&l=en&o=2514141-1&h=1305209141&u=http%3A%2F%2Fwww.csl.com%2F&a=CSL+Limited )

(ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more

than 22,000 people, and delivers its life-saving therapies to people in more

than 60 countries. For inspiring stories about the promise of biotechnology,

visit Vita CSLBehring.com/vita (https://c212.net/c/link/?t=0&l=en&o=2514141-1&h=1877328435&u=http%3A%2F%2Fwww.cslbehring.com%2Fvita&a=CSLBehring.com%2Fvita )

and follow us on www.Twitter.com/CSLBehring.

SOURCE: CSL Behring

CONTACT: Jennifer Purdue, Office: +1 610 878 4802, Mobile: +1 610 306 9355,

Email: jennifer.purdue@cslbehring.com